研究单位：[1]Shanghai Zhongshan Hospital[2]Peking University Cancer Hospital & Institute[3]Shanghai Chest Hospital[4]First Affiliated Hospital of Wenzhou Medical University[5]Tianjin Medical University Cancer Institute and Hospital[6]Ningbo Medical Center Lihuili Hospital[7]The First People's Hospital of Changzhou[8]Zhongshan Hospital (Xiamen), Fudan University[9]Xuhui Central Hospital, Shanghai[10]Shanghai Minhang Central Hospital[11]Cancer Institute and Hospital, Chinese Academy of Medical Sciences[12]Zhejiang Cancer Hospital[13]Sichuan Cancer Hospital and Research Institute[14]Tongji Hospital[15]Sun Yat-sen University[16]Shanghai Fifth People's Hospital
The purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy for locally advanced resectable esophageal squamous cell carcinoma (cII-III Stage) patient.
